Nivolumab in a patient with NSCLC: a protracted but effective treatment full of toxicities - case report

Abstract

Immunotherapy is now a standard part of the therapeutic algorithm for patients with non-small cell lung cancer. It is a major therapeutic advance and offers hope for long-term survival.

This treatment comes with its own unique set of toxicities. Their occurrence is not as frequent as with cytostatic therapy, but they are often more difficult to manage and can be severe, leading to the discontinuation of immunotherapy.

One of the drugs in this category is nivolumab, which was administered to our patient as a second-line treatment. Although various side effects accompanied the treatment, the patient benefited, and we made every effort to maintain her on this effective, modern therapy.